Full Text View
Tabular View
No Study Results Posted
Related Studies
Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk (TAXI)
This study has been completed.
Study NCT00682292   Information provided by University Hospital, Lille
First Received: May 20, 2008   Last Updated: May 21, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Renal Transplantation
Interventions listed in this trial
Thymoglobulin (ATG)
Daclizumab
More general drug interventions related to this trial
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
University Hospital, Lille
Erasme University Hospital


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services